Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

Dazukibart, an anti–interferon beta monoclonal antibody, showed potential in reducing dermatomyositis symptoms, with ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria.

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...